CY1120646T1 - Προγονικα κυτταρα μεσοδερμικης προελευσης - Google Patents

Προγονικα κυτταρα μεσοδερμικης προελευσης

Info

Publication number
CY1120646T1
CY1120646T1 CY181100736T CY181100736T CY1120646T1 CY 1120646 T1 CY1120646 T1 CY 1120646T1 CY 181100736 T CY181100736 T CY 181100736T CY 181100736 T CY181100736 T CY 181100736T CY 1120646 T1 CY1120646 T1 CY 1120646T1
Authority
CY
Cyprus
Prior art keywords
origin
intermederal
original cells
cells
original
Prior art date
Application number
CY181100736T
Other languages
Greek (el)
English (en)
Inventor
Thomas Averell Houze
Martin John Evans
Ajan Reginald
Ina Laura Pieper
Brian Lee Perkins
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1111503.7A external-priority patent/GB201111503D0/en
Priority claimed from GBGB1111505.2A external-priority patent/GB201111505D0/en
Priority claimed from GBGB1111509.4A external-priority patent/GB201111509D0/en
Priority claimed from GBGB1111500.3A external-priority patent/GB201111500D0/en
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of CY1120646T1 publication Critical patent/CY1120646T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
CY181100736T 2011-07-06 2018-07-16 Προγονικα κυτταρα μεσοδερμικης προελευσης CY1120646T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1111503.7A GB201111503D0 (en) 2011-07-06 2011-07-06 Heart failure (HF) MSC subtype
GBGB1111505.2A GB201111505D0 (en) 2011-07-06 2011-07-06 MI MSC subtype
GBGB1111509.4A GB201111509D0 (en) 2011-07-06 2011-07-06 Orthopedic MSC subtype
GBGB1111500.3A GB201111500D0 (en) 2011-07-06 2011-07-06 Wet age-related macular degeneration MSC subtype
PCT/GB2012/051600 WO2013005053A2 (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Publications (1)

Publication Number Publication Date
CY1120646T1 true CY1120646T1 (el) 2019-12-11

Family

ID=46513785

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100736T CY1120646T1 (el) 2011-07-06 2018-07-16 Προγονικα κυτταρα μεσοδερμικης προελευσης

Country Status (19)

Country Link
US (3) US10472609B2 (cg-RX-API-DMAC7.html)
EP (1) EP2729562B1 (cg-RX-API-DMAC7.html)
JP (2) JP6607675B2 (cg-RX-API-DMAC7.html)
CN (2) CN107746830A (cg-RX-API-DMAC7.html)
AU (2) AU2012279995C1 (cg-RX-API-DMAC7.html)
CA (1) CA2840307C (cg-RX-API-DMAC7.html)
CY (1) CY1120646T1 (cg-RX-API-DMAC7.html)
DK (1) DK2729562T3 (cg-RX-API-DMAC7.html)
EA (1) EA029577B1 (cg-RX-API-DMAC7.html)
ES (1) ES2675693T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181152T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039236T2 (cg-RX-API-DMAC7.html)
IL (2) IL230071B (cg-RX-API-DMAC7.html)
LT (1) LT2729562T (cg-RX-API-DMAC7.html)
MY (1) MY185016A (cg-RX-API-DMAC7.html)
PL (1) PL2729562T3 (cg-RX-API-DMAC7.html)
PT (1) PT2729562T (cg-RX-API-DMAC7.html)
SG (1) SG10201605518XA (cg-RX-API-DMAC7.html)
WO (1) WO2013005053A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
EP2782555B1 (en) 2011-11-23 2019-03-13 Cell Therapy Limited Platelet lysate gel
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
GB201410504D0 (en) 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
US20170248596A1 (en) * 2014-08-29 2017-08-31 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject
WO2016131430A1 (en) * 2015-02-20 2016-08-25 Shih-Chieh Hung Use of mesenchymal stem cells in treating osteoarthritis
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
CN108138136B (zh) * 2015-09-11 2022-02-11 安斯泰来制药株式会社 制造肾前体细胞的方法
GB201518263D0 (en) 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
CN105483206B (zh) * 2016-01-06 2019-09-13 北京汉氏联合生物技术股份有限公司 一种用vcam-1检测msc促内皮细胞增殖能力的方法
JP7219211B2 (ja) * 2016-08-29 2023-02-07 ハッケンサック ユニヴァーシティ メディカル センター ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法
IL264815B2 (en) * 2016-08-29 2024-09-01 Univ Hackensack Medical Center Preparations and methods for reprogramming cells of an adult with a platelet-rich fraction of blood containing platelet-like cells
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
JP7009977B2 (ja) * 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
PL3880217T3 (pl) * 2018-11-14 2024-05-20 Onderzoeks en Ontwikkelingsfonds Rode Kruis-Vlaanderen Sposoby otrzymywania materiału uwalnianego z płytek krwi
CN109329270A (zh) * 2018-11-19 2019-02-15 成都清科生物科技有限公司 一种静脉回输用间充质干细胞保存液及其制备方法
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
AU2020209441B2 (en) 2019-01-15 2025-07-31 Cell Therapy Limited Mesodermal killer (MK) cell
US20220160776A1 (en) * 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
CN113811295A (zh) * 2019-05-15 2021-12-17 永生公司 高浓度细胞包装和运送
CN110237094B (zh) * 2019-07-30 2023-10-03 天晴干细胞股份有限公司 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
RU2138162C1 (ru) 1997-04-17 1999-09-27 Суханов Владимир Александрович Способ криоконсервации богатой тромбоцитами плазмы
DE69837491T2 (de) 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. Menschliche mesenchymale stammzellen aus peripherem blut
AU9127098A (en) 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6387367B1 (en) 1998-05-29 2002-05-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
JP2003055237A (ja) * 2001-08-15 2003-02-26 Japan Science & Technology Corp 骨再生促進剤
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
US20050118714A1 (en) 2002-02-19 2005-06-02 Chul-Won Ha Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood and differentation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues
KR100534215B1 (ko) 2003-11-11 2005-12-08 (주)히스토스템 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법
DE102005011570A1 (de) 2004-04-13 2005-11-03 Man Roland Druckmaschinen Ag Prägeeinrichtung für Bedruckstoffe mit strukturierter Oberfläche in einer Bogendruckmaschine
ATE494360T1 (de) 2004-07-20 2011-01-15 Univ Case Western Reserve Neue zellpopulationen und deren anwendungen
CN102391981B (zh) 2004-09-24 2014-08-20 麦索布莱斯特公司 多能扩增间充质前体细胞子代(memp)及其应用
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
WO2006108229A1 (en) 2005-04-12 2006-10-19 Angioblast Systems, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
EP1971679B1 (en) 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
EP1845154A1 (en) 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
CN101516385B (zh) 2006-07-12 2013-07-10 成血管细胞系统公司 过量新血管化的治疗
US20090253151A1 (en) 2006-09-01 2009-10-08 Stempeutics Research Private Limited Self-Renewing Master Adult Pluripotent Stem Cells
WO2008097828A2 (en) 2007-02-02 2008-08-14 St. Jude Children's Research Hospital Method for isolating mesenchymal stromal cells
WO2008129563A2 (en) 2007-04-23 2008-10-30 Stempeutics Research Private Limited, Human mesenchymal stem cells and preparation thereof
US20090053182A1 (en) 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP2014294A1 (en) 2007-07-13 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of CD200 as a mesenchymal stem cells marker
WO2009044943A1 (en) 2007-10-01 2009-04-09 Seoul National University Industry Foundation Various human dental stem cells having a mineralization ability and the method for culturing them
MX2010000393A (es) 2007-11-09 2010-05-19 Rnl Bio Co Ltd Metodo para el aislamiento y cultivo de celulas madre adultas derivadas del epitelio amniotico humano.
WO2009069991A2 (en) * 2007-11-30 2009-06-04 Rnl Bio Co., Ltd. Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PROCESSORS AND EXPANSION UNDER NON-TERMS OF CONDITION
CN102076844B (zh) 2008-06-30 2013-08-07 成血管细胞系统公司 采用组合疗法的眼病和过度血管新生的治疗
WO2010017216A2 (en) 2008-08-04 2010-02-11 Allocure Mesenchymal stromal cell populations and methods of isolating and using same
ES2707274T3 (es) 2008-08-18 2019-04-03 Mesoblast Inc Uso de la proteína beta de shock térmico de 90 kDa como marcador para la identificación y/o enriquecimiento de las células precursoras mesenquimales multipotenciales adultas
WO2010021412A1 (ja) * 2008-08-22 2010-02-25 財団法人ヒューマンサイエンス振興財団 脳梗塞治療材及び脳組織再生方法
WO2010033605A2 (en) 2008-09-16 2010-03-25 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
CN104546912B (zh) 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
JP5647230B2 (ja) 2009-04-28 2014-12-24 アントロジェン カンパニー リミテッドＡｎｔｅｒｏｇｅｎ Ｃｏ．， Ｌｔｄ． 瘻孔治療のための自家及び同種異系の脂肪由来間質幹細胞組成物
EP2488187A4 (en) 2009-10-13 2014-03-26 Allocure Inc ASSAY FOR PREDICTING THE THERAPEUTIC EFFECT OF MECHANICAL CYCLES AND METHOD OF USE THEREOF
ES2358146B1 (es) 2009-10-22 2012-03-23 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis.
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
CN102048756B (zh) 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
US8703487B2 (en) 2009-12-01 2014-04-22 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
AU2011274255B2 (en) 2010-07-02 2016-05-05 Mesoblast, Inc. Treatment of T-cell mediated immune disorders
AU2011293144B2 (en) 2010-08-27 2015-04-23 Hare, Joshua M Bone marrow derived CD271 precursor cells for cardiac repair
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
ES2384790B1 (es) 2010-12-10 2013-05-20 Instituto De Salud Carlos Iii Células madre mesenquimales aisladas a partir de sangre periférica.
US20120288480A1 (en) 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
CN102078644A (zh) * 2011-03-08 2011-06-01 吉林大学 一种简便高效的自体富血小板血浆提取装置及提取方法
ES2833076T3 (es) 2011-05-19 2021-06-14 Mesoblast Inc Métodos para el tratamiento de la obesidad y/o el síndrome metabólico
ES2716015T3 (es) 2011-06-03 2019-06-07 Mesoblast Inc Procedimiento para tratar los efectos de un accidente cerebrovascular
CA2837895C (en) 2011-06-03 2021-07-27 Mesoblast, Inc. Methods of treating or preventing neurological diseases
ES3013463T3 (en) 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
WO2013033777A1 (en) 2011-09-09 2013-03-14 Mesoblast, Inc Methods for increasing osteoblastic function
AU2013219945B2 (en) 2012-02-13 2017-12-07 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2013151725A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome

Also Published As

Publication number Publication date
EP2729562B1 (en) 2018-04-18
US20200048613A1 (en) 2020-02-13
IL230071B (en) 2019-02-28
DK2729562T3 (en) 2018-07-23
PT2729562T (pt) 2018-07-18
AU2012279995A1 (en) 2014-01-23
US20150071886A1 (en) 2015-03-12
JP2014520523A (ja) 2014-08-25
ES2675693T3 (es) 2018-07-11
CA2840307C (en) 2021-10-19
US10472609B2 (en) 2019-11-12
EA201391773A1 (ru) 2014-11-28
AU2017204559A1 (en) 2017-07-20
CN104508124A (zh) 2015-04-08
HUE039236T2 (hu) 2018-12-28
US20210032600A1 (en) 2021-02-04
MY185016A (en) 2021-04-30
WO2013005053A2 (en) 2013-01-10
US11873513B2 (en) 2024-01-16
CN104508124B (zh) 2017-11-17
SG10201605518XA (en) 2016-08-30
US10829739B2 (en) 2020-11-10
AU2012279995C1 (en) 2019-10-24
CN107746830A (zh) 2018-03-02
IL264455A (en) 2019-02-28
PL2729562T3 (pl) 2018-10-31
CA2840307A1 (en) 2013-01-10
LT2729562T (lt) 2018-07-25
AU2012279995B2 (en) 2017-03-30
NZ620283A (en) 2016-06-24
EA029577B1 (ru) 2018-04-30
HRP20181152T1 (hr) 2018-09-21
JP6607675B2 (ja) 2019-11-20
WO2013005053A3 (en) 2013-06-13
EP2729562A2 (en) 2014-05-14
JP2017225451A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
PL3003330T4 (pl) Terapia przywracająca mikrobiota (MRT), kompozycje i sposoby wytwarzania
UY34254A (es) Proteínas y péptidos modificados.
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
UY34763A (es) Inhibidores de la agregación plaquetaria
UY4234Q (es) Configuración aplicada en zapato
UY34683A (es) Esteviol glucosiltransferasas y genes que las codifican
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
BR112015012907A2 (pt) composição de cuidado pessoal
UA110470C2 (ru) Антидот антикоагулянта
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
TWD158887S (zh) 粉餅盒
UY4281Q (es) Juguera
UY34200A (es) 3-(fluorovinil)pirazoles y su uso